Insights: Publications Compulsory Licensing To Cut Drug Costs Could Harm Public
Law360
Prescription drug prices, and means by which the executive branch might lower them absent legislative action, were a hot topic during the 2020 election, particularly during the Democratic primary. Multiple candidates laid out plans for presidential oversight of drug pricing.
After Joe Biden won the election, Sen. Elizabeth Warren, D-Mass., called for the president-elect to "[l]ower drug prices ... using existing compulsory licensing authority."
Where does the government's power to impose compulsory licenses come from? And should Biden utilize compulsory licensing to rein in perceived staggering price tags attached to certain critically important drug products in the U.S.?
Related People
Related Industries
Disclaimer
While we are pleased to have you contact us by telephone, surface mail, electronic mail, or by facsimile transmission, contacting Kilpatrick Townsend & Stockton LLP or any of its attorneys does not create an attorney-client relationship. The formation of an attorney-client relationship requires consideration of multiple factors, including possible conflicts of interest. An attorney-client relationship is formed only when both you and the Firm have agreed to proceed with a defined engagement.
DO NOT CONVEY TO US ANY INFORMATION YOU REGARD AS CONFIDENTIAL UNTIL A FORMAL CLIENT-ATTORNEY RELATIONSHIP HAS BEEN ESTABLISHED.
If you do convey information, you recognize that we may review and disclose the information, and you agree that even if you regard the information as highly confidential and even if it is transmitted in a good faith effort to retain us, such a review does not preclude us from representing another client directly adverse to you, even in a matter where that information could be used against you.
